Loading patent…
AssigneesTechnophage, InvestigaçãO E Desenvolvimento Em Biotecnologia, SA, Tecnifar—Industria Tecnica Farmaceutica, S.A.
InventorsSofia Valker Côrte-Real, Miguel Ângelo Costa Garcia, Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa
Estimating the term…
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.
A pharmaceutical composition comprising at least two different purified bacteriophages, each comprising a nucleic acid having a nucleotide sequence which has at least 97% sequence identity to SEQ ID NO:1 (F99/10), at least 97% sequence identity to SEQ ID NO:2 (F110/10), at least 97% sequence identity to SEQ ID NO:3 (F27/12), at least 95% sequence identity to SEQ ID NO:4 (F83/13), at least 97% sequence identity to SEQ ID NO:5 (F95/13), at least 90% sequence identity to SEQ ID NO:6 (F391/08), at least 90% sequence identity to SEQ ID NO:7 (F92/15), at least 99% sequence identity to SEQ ID NO:8 (F105/15), at least 98% sequence identity to SEQ ID NO:9 (F134/15), or at least 95% sequence identity to SEQ ID NO:10 (F141/15), or variants thereof and having antibacterial activity against Pseudomonas aeruginosa and/or Klebsiella pneumoniae.
A purified bacteriophage comprising a nucleic acid having a nucleotide sequence which has at least 97% sequence identity to SEQ ID NO:1 (F99/10), at least 97% sequence identity to SEQ ID NO:2 (F110/10), at least 97% sequence identity to SEQ ID NO:3 (F27/12), at least 95% sequence identity to SEQ ID NO:4 (F83/13), at least 97% sequence identity to SEQ ID NO:5 (F95/13), at least 90% sequence identity to SEQ ID NO:7 (F92/15), at least 99% sequence identity to SEQ ID NO:8 (F105/15), at least 98% sequence identity to SEQ ID NO:9 (F134/15), or at least 95% sequence identity to SEQ ID NO:10 (F141/15), or variant thereof and having antibacterial activity against Pseudomonas aeruginosa or Klebsiella pneumoniae.
Dependencies are inferred from the claim text.